{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:05:27Z","timestamp":1792530327284,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-13721-w","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T17:24:43Z","timestamp":1754328283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Surface functionalized albumin nanoparticles of palbociclib with amplified brain delivery for treating brain glioblastoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Vishwanath","family":"Kurawattimath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnabas","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kannoth Mukundan","family":"Geetha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpana","family":"Divekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"issue":"12 Suppl 2","key":"13721_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","volume":"22","author":"QT Ostrom","year":"2020","unstructured":"Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and other central nervous system tumorsdiagnosed in the united States in 2013\u20132017. Neuro Oncol. 22 (12 Suppl 2), iv1\u2013iv96 (2020).","journal-title":"Neuro Oncol."},{"key":"13721_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N Engl. J. Med. 352, 987\u2013996 (2005).","journal-title":"N Engl. J. Med."},{"key":"13721_CR3","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMra0708126","volume":"359","author":"PY Wen","year":"2008","unstructured":"Wen, P. Y. & Kesari, S. Malignant gliomas in adults. N Engl. J. Med. 359, 492\u2013507 (2008).","journal-title":"N Engl. J. Med."},{"key":"13721_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/978-1-60327-492-0_14","volume":"472","author":"H Ohgaki","year":"2009","unstructured":"Ohgaki, H. Epidemiology of brain tumors. Methods Mol. Biol. 472, 323\u2013342 (2009).","journal-title":"Methods Mol. Biol."},{"key":"13721_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11060-006-9292-0","volume":"83","author":"R Martinez","year":"2007","unstructured":"Martinez, R. et al. Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. J. Neurooncol. 83, 91\u201393 (2007).","journal-title":"J. Neurooncol"},{"key":"13721_CR6","doi-asserted-by":"publisher","first-page":"105780","DOI":"10.1016\/j.phrs.2021.105780","volume":"171","author":"W Wu","year":"2021","unstructured":"Wu, W. et al. Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol. Res. 171, 105780 (2021).","journal-title":"Pharmacol. Res."},{"key":"13721_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/pharmaceutics15010059","volume":"15","author":"HK Brar","year":"2023","unstructured":"Brar, H. K., Jose, J., Wu, Z. & Sharma, M. Tyrosine kinase inhibitors for glioblastoma multiforme: challenges and opportunities for drug delivery. Pharmaceutics 15, 59 (2023).","journal-title":"Pharmaceutics"},{"key":"13721_CR8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3390\/pharmaceutics13040492","volume":"13","author":"CA Rene","year":"2021","unstructured":"Rene, C. A. & Parks, R. J. Delivery of therapeutic agents to the central nervous system and the promise of extracellular vesicles. Pharmaceutics 13, 492 (2021).","journal-title":"Pharmaceutics"},{"issue":"4","key":"13721_CR9","doi-asserted-by":"publisher","first-page":"e273","DOI":"10.3747\/co.22.2436","volume":"22","author":"O Gallego","year":"2015","unstructured":"Gallego, O. Nonsurgical treatment of recurrent glioblastoma. Curr. Oncol. 22 (4), e273\u2013281 (2015).","journal-title":"Curr. Oncol."},{"issue":"9","key":"13721_CR10","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1097\/01.cad.0000231473.00030.1f","volume":"17","author":"S Sathornsumetee","year":"2006","unstructured":"Sathornsumetee, S. & Rich, J. N. New approaches to primary brain tumor treatment. Anticancer Drugs. 17 (9), 1003\u20131016 (2006).","journal-title":"Anticancer Drugs"},{"issue":"3","key":"13721_CR11","first-page":"223","volume":"12","author":"YY Xu","year":"2015","unstructured":"Xu, Y. Y., Gao, P., Sun, Y. & Duan, Y. R. Development of targeted therapies in treatment of glioblastoma. Cancer Biol. Med. 12 (3), 223\u2013237 (2015).","journal-title":"Cancer Biol. Med."},{"key":"13721_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jneumeth.2018.10.015","volume":"311","author":"W Barnabas","year":"2019","unstructured":"Barnabas, W. Drug targeting strategies into the brain for treating neurological diseases. J. Neurosci. Methods. 311, 133\u2013146 (2019).","journal-title":"J. Neurosci. Methods"},{"issue":"1","key":"13721_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/cancers7010179","volume":"7","author":"M Peyressatre","year":"2015","unstructured":"Peyressatre, M., Pr\u00e9vel, C., Pellerano, M. & Morris, M. C. Targeting cyclin-dependent kinases in human cancers: from small molecules to peptide inhibitors. Cancers (Basel). 7 (1), 179\u2013237 (2015).","journal-title":"Cancers (Basel)"},{"issue":"7","key":"13721_CR14","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1021\/jm049354h","volume":"48","author":"PL Toogood","year":"2005","unstructured":"Toogood, P. L. et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4\/6. J. Med. Chem. 48 (7), 2388\u20132406 (2005).","journal-title":"J. Med. Chem."},{"key":"13721_CR15","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. N Engl. J. Med. 375, 1925\u20131936 (2016).","journal-title":"N Engl. J. Med."},{"key":"13721_CR16","doi-asserted-by":"publisher","first-page":"212579","DOI":"10.7573\/dic.212579","volume":"8","author":"F Serra","year":"2019","unstructured":"Serra, F. et al. Palbociclib in metastatic breast cancer: current evidence and real-life data. Drugs Context. 8, 212579 (2019).","journal-title":"Drugs Context"},{"key":"13721_CR17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11523-024-01046-z","volume":"19","author":"E Brain","year":"2024","unstructured":"Brain, E. et al. Palbociclib in older patients with advanced\/metastatic breast cancer: A systematic review. Target. Oncol. 19, 303\u2013320 (2024).","journal-title":"Target. Oncol."},{"key":"13721_CR18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s11060-018-2977-3","volume":"140","author":"JW Taylor","year":"2018","unstructured":"Taylor, J. W. et al. Phase-2 trial of Palbociclib in adult patients with recurrent RB1-positive glioblastoma. J. Neurooncol. 140, 477\u2013483 (2018).","journal-title":"J. Neurooncol"},{"key":"13721_CR19","doi-asserted-by":"publisher","first-page":"e28879","DOI":"10.1002\/pbc.28879","volume":"68","author":"D van Mater","year":"2021","unstructured":"van Mater, D. et al. A phase I trial of the CDK 4\/6 inhibitor Palbociclib in pediatric patients with progressive brain tumors: A pediatric brain tumor consortium study (PBTC-042). Pediatr. Blood Cancer. 68, e28879 (2021).","journal-title":"Pediatr. Blood Cancer"},{"key":"13721_CR20","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1007\/s10637-015-0266-y","volume":"33","author":"MC De Gooijer","year":"2015","unstructured":"De Gooijer, M. C. et al. P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4\/6 inhibitor Palbociclib. Invest. New. Drugs. 33, 1012\u20131019 (2015).","journal-title":"Invest. New. Drugs"},{"key":"13721_CR21","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1021\/acs.molpharmaceut.9b00475","volume":"16","author":"A Mart\u00ednez-Ch\u00e1vez","year":"2019","unstructured":"Mart\u00ednez-Ch\u00e1vez, A. et al. P-glycoprotein limits ribociclib brain exposure and CYP3A4 restricts its oral bioavailability. Mol. Pharm. 16, 3842\u20133852 (2019).","journal-title":"Mol. Pharm."},{"key":"13721_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.brainres.2008.01.039","volume":"1200","author":"B Wilson","year":"2008","unstructured":"Wilson, B. et al. Poly (n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of Rivastigmine into the brain to treat alzheimer\u2019s disease. Brain Res. 1200, 159\u2013168 (2008).","journal-title":"Brain Res."},{"key":"13721_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejpb.2008.03.009","volume":"70","author":"B Wilson","year":"2008","unstructured":"Wilson, B. et al. Targeted delivery of Tacrine into the brain with Polysorbate 80-coated Poly (n-butylcyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm. 70, 75\u201384 (2008).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"13721_CR24","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.ijbiomac.2015.09.015","volume":"81","author":"B Wilson","year":"2015","unstructured":"Wilson, B., Paladugu, L., Priyadarshini, S. R. B. & Jenita, J. J. L. Development of albumin-based nanoparticles for the delivery of abacavir. Int. J. Biol. Macromol. 81, 763\u2013767 (2015).","journal-title":"Int. J. Biol. Macromol."},{"key":"13721_CR25","first-page":"525","volume":"5","author":"S Sebak","year":"2010","unstructured":"Sebak, S., Mirzaei, M., Malhotra, M., Kulamarva, A. & Prakash, S. Human serum albumin nanoparticles as an efficient Noscapine drug delivery system for potential use in breast cancer: Preparation and in vitro analysis. Int. J. Nanomed. 5, 525\u2013532 (2010).","journal-title":"Int. J. Nanomed."},{"issue":"2","key":"13721_CR26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1021\/mp400436d","volume":"11","author":"TT Mariappan","year":"2014","unstructured":"Mariappan, T. T. et al. Estimation of the unbound brain concentration of P-glycoprotein substrates or nonsubstrates by a serial cerebrospinal fluid sampling technique in rats. Mol. Pharm. 11 (2), 477\u2013485 (2014).","journal-title":"Mol. Pharm."},{"issue":"2","key":"13721_CR27","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1016\/j.arabjc.2019.05.005","volume":"13","author":"M Al-Shehri","year":"2020","unstructured":"Al-Shehri, M. et al. Development and validation of an UHPLC-MS\/MS method for simultaneous determination of palbociclib, letrozole and its metabolite carbinol in rat plasma and Pharmacokinetic study application. Arab. J. Chem. 13 (2), 4024\u20134034 (2020).","journal-title":"Arab. J. Chem."},{"key":"13721_CR28","doi-asserted-by":"publisher","first-page":"115004","DOI":"10.1088\/2053-1591\/abc772","volume":"7","author":"SY Iftikhar","year":"2020","unstructured":"Iftikhar, S. Y., Iqbal, F. M., Hassan, W., Nasir, B. & Sarwar, A. R. Desirability combined response surface methodology approach for optimization of prednisolone acetate loaded Chitosan nanoparticles and in-vitro assessment. Mater. Res. Express. 7, 115004 (2020).","journal-title":"Mater. Res. Express"},{"key":"13721_CR29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.colsurfb.2009.08.049","volume":"75","author":"R Tantra","year":"2010","unstructured":"Tantra, R., Tompkins, J. & Quincey, P. Characterisation of the de-agglomeration effects of bovine serum albumin on nanoparticles in aqueous suspension. Colloids Surf. B Biointerfaces. 75, 275\u2013281 (2010).","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"13721_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0378-5173(90)90047-8","volume":"61","author":"SD Troster","year":"1990","unstructured":"Troster, S. D. & M\u00fcller, U. Modification of the body distribution of poly(methylmethacrylate) nanoparticles in rats by coating with surfactants. Int. J. Pharm. 61, 85\u2013100 (1990).","journal-title":"Int. J. Pharm."},{"key":"13721_CR31","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0006-8993(95)00023-J","volume":"674","author":"J Kreuter","year":"1995","unstructured":"Kreuter, J., Alyautdin, R. N., Kharkevich, D. A. & Ivanov, A. A. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 674, 171\u2013174 (1995).","journal-title":"Brain Res."},{"key":"13721_CR32","first-page":"44","volume":"41","author":"RN Alyautdin","year":"1995","unstructured":"Alyautdin, R. N., Gothier, D., Petrov, V. E., Kharkevich, D. A. & Kreuter, J. Analgesic activity of the hexapeptide Dalargin adsorbed on the surface of polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm. 41, 44\u201348 (1995). (1995).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"13721_CR33","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.2147\/IJN.S132780","volume":"12","author":"S Shen","year":"2017","unstructured":"Shen, S., Wu, Y., Liu, Y. & Wu, D. High drug-loading nanomedicines: progress, current status, and prospects. Int. J. Nanomed. 12, 4085\u20134109 (2017).","journal-title":"Int. J. Nanomed."},{"key":"13721_CR34","first-page":"3752","volume":"55","author":"F Yuan","year":"1995","unstructured":"Yuan, F. & Et Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55, 3752\u20133756 (1995).","journal-title":"Cancer Res."},{"key":"13721_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00118-6","volume":"47","author":"RH Muller","year":"2001","unstructured":"Muller, R. H., Jacobs, C. & Kayser, O. Nanosuspensions as particulate drug formulations in therapy, rationale for development and what we can expect for the future. Adv. Drug Deliv Rev. 47, 3\u201319 (2001).","journal-title":"Adv. Drug Deliv Rev."},{"key":"13721_CR36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ijpharm.2004.11.027","volume":"290","author":"RM Mainardes","year":"2005","unstructured":"Mainardes, R. M. & Evangelista, R. C. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int. J. Pharm. 290, 137\u2013144 (2005).","journal-title":"Int. J. Pharm."},{"key":"13721_CR37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/jbm.a.30654","volume":"77","author":"DS Kohane","year":"2006","unstructured":"Kohane, D. S., Tse, J. Y., Yeo, Y., Padera, R. & Shubina, M. Robert, L. Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum. J. Biomed. Mater. Res. 77, 351\u2013361 (2006).","journal-title":"J. Biomed. Mater. Res."},{"key":"13721_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0168-3659(01)00486-2","volume":"78","author":"A Vila","year":"2002","unstructured":"Vila, A., S\u00e1nchez, A., Tob\u00edo, M., Calvo, P. & Alonso, M. J. Design of biodegradable particles for protein delivery. J. Control Release. 78, 15\u201324 (2002).","journal-title":"J. Control Release"},{"issue":"1","key":"13721_CR39","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.nano.2009.04.001","volume":"6","author":"B Wilson","year":"2010","unstructured":"Wilson, B. et al. Chitosan nanoparticles as a novel delivery system for anti-Alzheimer\u2019s drug Tacrine. Nanomed. Nanotech Biol. Med. 6 (1), 144\u2013152 (2010).","journal-title":"Nanomed. Nanotech Biol. Med."},{"key":"13721_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jconrel.2004.08.010","volume":"100","author":"SA Agnihotri","year":"2004","unstructured":"Agnihotri, S. A., Mallikarjuna, N. N. & Aminabhavi, T. M. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J. Control Release. 100, 5\u201328 (2004).","journal-title":"J. Control Release"},{"key":"13721_CR41","doi-asserted-by":"publisher","first-page":"599","DOI":"10.4155\/tde.11.21","volume":"2","author":"B Wilson","year":"2011","unstructured":"Wilson, B., Samanta, M. K. & Suresh, B. Design and evaluation of Chitosan nanoparticles as novel drug carrier for the delivery of Rivastigmine to treat alzheimer\u2019s disease. Ther. Deliv. 2, 599\u2013609 (2011).","journal-title":"Ther. Deliv"},{"key":"13721_CR42","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1023\/A:1016064930502","volume":"13","author":"BG Muller","year":"1996","unstructured":"Muller, B. G., Leuenberger, H. & Kissel, T. Albumin nanospheres as carriers for passive drug targeting: an optimized manufacturing technique. Pharm. Res. 13, 32\u201337 (1996).","journal-title":"Pharm. Res."},{"issue":"2","key":"13721_CR43","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0928-0987(01)00095-1","volume":"13","author":"P Costa","year":"2001","unstructured":"Costa, P. & Lobo, S. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13 (2), 123\u2013133 (2001).","journal-title":"Eur. J. Pharm. Sci."},{"key":"13721_CR44","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0378-5173(03)00134-0","volume":"257","author":"K Langer","year":"2003","unstructured":"Langer, K. et al. Optimization of the Preparation process for human serum albumin (HAS) nanoparticles. Int. J. Pharm. 257, 169\u2013180 (2003).","journal-title":"Int. J. Pharm."},{"key":"13721_CR45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/0021-9797(84)90015-8","volume":"101","author":"SJ Douglas","year":"1984","unstructured":"Douglas, S. J., Illum, L., Davis, S. S. & Kreuter, J. Particle size and size distribution of poly(butyl-2-cyanoacrylate) nanoparticles. J. Col Interf Sci. 101, 49\u201358 (1984).","journal-title":"J. Col Interf Sci."},{"key":"13721_CR46","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1002\/jps.2600730730","volume":"73","author":"V Lenaerts","year":"1984","unstructured":"Lenaerts, V. Et al. In vivo uptake of poly(isobutylcyanoacrylate) nanoparticles by the rat liver kupffer, endothelial and parenchymal cells. J. Pharm. Sci. 73, 980\u2013982 (1984).","journal-title":"J. Pharm. Sci."},{"key":"13721_CR47","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/BF02897257","volume":"26","author":"N Chiannilkulchai","year":"1990","unstructured":"Chiannilkulchai, N., Ammoury, N., Caillou, B., Devissageut, J. & Couvreur, P. Hepatic tissue distribution of doxorubicin loaded nanoparticles after i.v. Administration in reticulosarcoma M 5076 metastases-bearing mice. Cancer Chemother. Pharmacol. 26, 122\u2013126 (1990).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"13721_CR48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0168-3659(97)00105-3","volume":"50","author":"R L\u00f6benberg","year":"1998","unstructured":"L\u00f6benberg, R., Araujo, L., von Brisen, H., Rodgers, E. & Kreuter, J. Body distribution of Azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. Injection to rats. J. Control Release. 50, 21\u201330 (1998).","journal-title":"J. Control Release"},{"key":"13721_CR49","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0378-5173(94)90372-7","volume":"110","author":"G Borchard","year":"1994","unstructured":"Borchard, G., Audus, K. L., Shi, F. & Kreuter, J. Uptake of surfactant-coated poly(methylmethacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers. Int. J. Pharm. 110, 29\u201335 (1994).","journal-title":"Int. J. Pharm."},{"key":"13721_CR50","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijpharm.2014.05.056","volume":"473","author":"B Wilson","year":"2014","unstructured":"Wilson, B., Lavanya, Y., Priyadarshini, S. R. B., Ramasamy, M. & Jenita, J. J. L. Albumin nanoparticles for the delivery of gabapentin: preparation, characterization and pharmacodynamic studies. Int. J. Pharm. 473, 73\u201379 (2014).","journal-title":"Int. J. Pharm."},{"key":"13721_CR51","first-page":"100128","volume":"10","author":"K Vishwanath","year":"2023","unstructured":"Vishwanath, K., Wilson, B. & Geetha, K. M. Nanoparticle-based drug delivery across the blood-brain barrier for treating malignant brain glioma. Open. Nano. 10, 100128 (2023).","journal-title":"Open. Nano"},{"key":"13721_CR52","doi-asserted-by":"publisher","first-page":"102176","DOI":"10.1016\/j.jddst.2020.102176","volume":"61","author":"B Wilson","year":"2021","unstructured":"Wilson, B., Alobaid, B. N. M., Geetha, K. M. & Jenita, J. L. Chitosan nanoparticles to enhance nasal absorption and brain targeting of sitagliptin to treat alzheimer\u2019s disease. J. Drug Deliv Sci. Technol. 61, 102176 (2021).","journal-title":"J. Drug Deliv Sci. Technol."},{"key":"13721_CR53","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4155\/tde-2022-0056","volume":"14","author":"K Vishwanath","year":"2023","unstructured":"Vishwanath, K., Wilson, B., Geetha, K. M. & Murugan, V. Polysorbate 80-coated albumin nanoparticles to deliver Paclitaxel into the brain to treat glioma. Ther. Deliv. 14, 193\u2013206 (2023).","journal-title":"Ther. Deliv"},{"key":"13721_CR54","doi-asserted-by":"publisher","first-page":"102793","DOI":"10.1016\/j.jddst.2021.102793","volume":"66","author":"KM Geetha","year":"2021","unstructured":"Geetha, K. M., Shankar, J. & Wilson, B. Potential applications of nanomedicine for treating parkinson\u2019s disease. J. Drug Deliv Sci. Technol. 66, 102793 (2021).","journal-title":"J. Drug Deliv Sci. Technol."},{"key":"13721_CR55","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jconrel.2020.05.044","volume":"325","author":"B Wilson","year":"2020","unstructured":"Wilson, B. & Geetha, K. M. Neurotherapeutic applications of nanomedicine for treating alzheimer\u2019s disease. J. Control Release. 325, 25\u201337 (2020).","journal-title":"J. Control Release"},{"key":"13721_CR56","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1023\/A:1012098005098","volume":"14","author":"RN Alyautdin","year":"1997","unstructured":"Alyautdin, R. N. et al. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles. Pharm. Res. 14, 325\u2013328 (1997).","journal-title":"Pharm. Res."},{"key":"13721_CR57","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3109\/02652049809006836","volume":"15","author":"RN Alyautdin","year":"1998","unstructured":"Alyautdin, R. N. et al. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles: an in situ brain perfusion study. J. Microencpsul. 15, 67\u201374 (1998).","journal-title":"J. Microencpsul"},{"key":"13721_CR58","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1023\/A:1018983904537","volume":"16","author":"AE Gulyaev","year":"1996","unstructured":"Gulyaev, A. E. et al. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 16, 1564\u20131569 (1996).","journal-title":"Pharm. Res."},{"key":"13721_CR59","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1016\/j.biomaterials.2003.09.087","volume":"25","author":"W Sun","year":"2004","unstructured":"Sun, W., Xie, C. & Wang, H. Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials 25, 3065\u20133071 (2004).","journal-title":"Biomaterials"},{"key":"13721_CR60","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0169-409X(00)00122-8","volume":"47","author":"J Kreuter","year":"2001","unstructured":"Kreuter, J. Nanoparticle systems for brain delivery of drugs. Adv. Drug Deliv Rev. 47, 65\u201381 (2001).","journal-title":"Adv. Drug Deliv Rev."},{"key":"13721_CR61","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jconrel.2006.12.012","volume":"118","author":"J Kreuter","year":"2007","unstructured":"Kreuter, J. et al. Covalent attachment of Apolipoprotein A-I and Apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J. Control Release. 118, 54\u201358 (2007).","journal-title":"J. Control Release"},{"key":"13721_CR62","unstructured":"Anonymous. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/21660_ABRAXANE_approv.PDF. (2005). Accessed on 13th April 2024."},{"key":"13721_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12668-024-01651-2","volume":"15","author":"B Wilson","year":"2025","unstructured":"Wilson, B., Geetha, K. M., Diveskar, K., Jenita, J. L. & Premakumari, K. B. Sagar, G. Albumin nanoparticle enhances oxaliplatin concentration in the colorectal region with increased efficacy. BioNanoScience 15, 1\u201310 (2025).","journal-title":"BioNanoScience"},{"key":"13721_CR64","first-page":"84","volume":"51","author":"B Wilson","year":"2012","unstructured":"Wilson, B., Ambika, T. V., Dharmeshkumar, P., Jenita, J. J. L. & Priyadarshini, S. R. B. Nanoparticles based on albumin: preparation, characterization and the use for 5-flurouracil delivery. Int. L J. Biol. Macromol. 51, 84\u201388 (2012).","journal-title":"Int. L J. Biol. Macromol."},{"key":"13721_CR65","doi-asserted-by":"publisher","first-page":"103553","DOI":"10.2217\/nnm-2019-0366","volume":"15","author":"B Wilson","year":"2020","unstructured":"Wilson, B. & Geetha, K. M. Artificial intelligence and related technologies enabled nanomedicine for advanced cancer treatment. Nanomed. (London). 15, 103553 (2020).","journal-title":"Nanomed. (London)"},{"key":"13721_CR66","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"WJ Gradishar","year":"2005","unstructured":"Gradishar, W. J. & Et Phase III trial of nanoparticle albumin-bound Paclitaxel compared with polyethylated castor oil-based Paclitaxel in women with breast cancer. J. Cli Oncol. 23, 7794\u20137803 (2005).","journal-title":"J. Cli Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13721-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13721-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13721-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T14:13:08Z","timestamp":1757340788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13721-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13721"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-13721-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"26 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"In this study, the animal experiments were carried out after getting approval from Institutional Animal Ethics Committee, College of Pharmaceutical Sciences, Dayananda Sagar University, Bengaluru, India (DSU\/Ph.D.\/IAEC\/20\/2018-19). The authors confirm that all the methods are reported in accordance with ARRIVE\/CCSEA guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"28433"}}